Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Table 2 Analysis of PLR in relation to overall survival in patients with g-NEN

Exposure	Crude model		Model I		Model II
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
PLR (per SD)	1.67 (1.32, 2.12)	< 0.001	1.63 (1.28, 2.08)	< 0.001	1.54 (1.20, 1.98)	0.001
PLR (quantile)
Q1 (< 103)	Ref		Ref		Ref
Q2 (>= 103–< 137)	1.58 (0.78, 3.18)	0.202	1.65 (0.82, 3.34)	0.162	1.59 (0.77, 3.30)	0.208
Q3 (>= 137–< 187)	2.03 (1.04, 3.96)	0.037	1.93 (0.97, 3.83)	0.060	1.63 (0.81, 3.30)	0.173
Q4 (>= 187)	2.77 (1.44, 5.34)	0.002	2.62 (1.35, 5.07)	0.004	2.55 (1.28, 5.09)	0.008
PLR (quantile)
Q1–Q3 (< 187)	Ref		Ref		Ref
Q4 (>= 187)	1.83 (1.15, 2.92)	0.011	1.73 (1.08, 2.76)	0.022	1.80 (1.10, 2.95)	0.020
BMI (continuous)	0.99 (0.94, 1.06)	0.959	1.01 (0.95, 1.07)	0.812	1.01 (0.95, 1.08)	0.782
BMI (categorical)
< 25	Ref		Ref		Ref
>= 25	0.88 (0.57, 1.36)	0.567	0.90 (0.58, 1.40)	0.641	0.98 (0.63, 1.53)	0.927

Abbreviations: SD standard deviation, CI indicates confidence interval, HR hazard ratio, PLR platelet to lymphocyte ratio, IQR interquartile range, BMI body mass index. The values in this table are expressed as the format of HR (95% CI). Crude model did not adjust covariant; Model I minimally adjusted for sex and age; Model II fully adjusted for sex, age, tumor size, and N stage

ISSN: 1477-7819